Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.

Benjamin J Solomon,Todd M Bauer,Tony S K Mok,Geoffrey Liu,Julien Mazieres,Filippo de Marinis,Yasushi Goto,Dong-Wan Kim,Yi-Long Wu,Jacek Jassem, Froylán López López,Ross A Soo,Alice T Shaw,Anna Polli,Rossella Messina,Laura Iadeluca,Francesca Toffalorio,Enriqueta Felip

FUTURE ONCOLOGY（2023）

引用 0|浏览51

暂无评分

摘要

The updated results from the CROWN study showed that a larger percentage of people who took lorlatinib continued to benefit from their treatment after being observed for 3 years compared with those who took crizotinib. NCT03052608 (phase 3 CROWN study) (ClinicalTrials.gov).

查看译文

关键词

clinical trial, crizotinib, lay summary, lorlatinib, non-small cell lung cancer, plain language summary

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要